How will the findings from the recent BOSS study affect your management of Barrett's esophagus without dysplasia?

The findings of the BOSS study are consistent with emerging data suggesting that the risk associated with nondysplastic Barrett’s esophagus (NDBE) is lower than previously estimated and that routine surveillance may not meaningfully alter clinical outcomes. Compared to symptom-driven (“at-need”) endoscopy, surveillance endoscopy did not demonstrate a reduction in all-cause mortality or the incidence of esophageal adenocarcinoma. These results are likely to influence forthcoming societal guidelin...